Do you want to read an article? Please log in or register.
The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes
Respiratory Tract Infection
Related content
RECOMMENDED
COPD
Use of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitor is Associated with reduced Emergency Room Visits and Hospitalization in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Diabetes Mellitus
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Shanmugavel Geetha H, Teo YX, Ravichandran S, Perkitt NR, Gogtay M, Lal A, Abraham GM, Trivedi N
doi: 10.1016/j.rmed.2024.107819
COMMENTED
COPD
Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ
doi: 10.1016/j.chest.2024.07.168
RECOMMENDED
COPDInterstitial Lung Disease
Pulmonary Rehabilitation and Functional Independence: Impact on Survival in Patients with Fibrotic Interstitial Lung Disease or Chronic Obstructive Pulmonary Disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Elmiger A, Marcin T, Bovet L, Brun P, Guler SA
doi: 10.1016/j.rmed.2024.107933
ARDSCOPDEmphysema
Clinical and biologic profiles of patients with acute respiratory distress syndrome by prevalence of chronic obstructive pulmonary disease or emphysema; a cohort study
Respir Res
Nath S, Qurashi H, Kitsios GD, Bain W, Aneis H, Suber T, Prendergast N, Hensley M, Schaefer C, Zhang Y, Bon J, McVerry BJ, Evankovich J, Shah FA
doi: 10.1186/s12931-024-03027-2
COPDEmphysema
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
Respir Med
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM
doi: 10.1016/j.rmed.2024.107846
RECOMMENDED
COPD
Prognostic risk prediction model for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a systematic review and meta-analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Xu Z, Li F, Xin Y, Wang Y, Wang Y
doi: 10.1186/s12931-024-03033-4
COPDLung Cancer
Construction and Validation of a Nomogram Prediction Model for Death Risk in Patients with Chronic Obstructive Pulmonary Disease Complicated by Hypercapnic Respiratory Failure in the Intensive Care Unit
Respir Med
Zhang Y, Chen H, Hu S, Chen C, Chen W
doi: 10.1016/j.rmed.2025.108188
COMMENTED
COPD
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB
doi: 10.1016/S2213-2600(24)00409-0
AsthmaCOPD
An assessment of written leaflets for enhancing patient education and counselling on asthma and chronic obstructive pulmonary disease in the implementation of a new medicine service in Poland
Sci Rep
Guzenda W, Jasińska-Stroschein M, Wawrowska A, Sierpniowska O, Jędra A, Przymuszała P, Dąbrowiecki P, Wiśniewska P, Waszyk-Nowaczyk M
doi: 10.1038/s41598-025-11163-y